Guardant Health appoints Steve E. Krognes to board of directors

Guardant Health, Inc.

Appointed as Class III director effective June 30, 2022, term expiring at 2024 annual meeting.
Will serve as audit committee chair and on the nominating and corporate governance committee.
Krognes previously CFO of Denali Therapeutics and Genentech; over 20 years biotech/life sciences.
Will receive standard non-employee director compensation: stock option and RSU each valued at $362,500.
Also enters into standard indemnification agreement with the Company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steve E. Krognes

Class III director

GH · Guardant Health, Inc.

Effective: 2022-06-30
Filed: July 7, 2022, 7:59 PM ET

Effective June 30, 2022, the Board of Directors (the “ Board ”) of Guardant Health, Inc. (the “ Company ”) increased the number of directors on the Board to eight and appointed Steve E. Krognes as a Class III director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve E. Krognes was appointed as Class III director at Guardant Health, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

Effective June 30, 2022, the Board of Directors (the “ Board ”) of Guardant Health, Inc. (the “ Company ”) increased the number of directors on the Board to eight and appointed Steve E. Krognes as a Class III director of the Company.

View on SEC.gov

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-189064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.